# VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

> **NCT03499795** · PHASE2 · COMPLETED · sponsor: **Inovio Pharmaceuticals** · enrollment: 23 (actual)

## Conditions studied

- Anal Neoplasm

## Interventions

- **BIOLOGICAL:** VGX-3100
- **DEVICE:** CELLECTRA™ 5PSP

## Key facts

- **NCT ID:** NCT03499795
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-15
- **Primary completion:** 2020-06-16
- **Final completion:** 2021-05-26
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03499795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03499795, "VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03499795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*